177478-52-3

Basic information

• Product Name: Acetamide, N-[4-(hydroxymethyl)-2-methoxyphenyl]-
• CAS NO: 177478-52-3
• Molecular Formula: C10H13NO3
• Molecular Weight: 195.218
• Mol File: 177478-52-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Acetamide, N-[4-(hydroxymethyl)-2-methoxyphenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-[4-(hydroxymethyl)-2-methoxyphenyl]-(177478-52-3)
• EPA Substance Registry System: Acetamide, N-[4-(hydroxymethyl)-2-methoxyphenyl]-(177478-52-3)

Safety Data

• Hazardous Substances Data: 177478-52-3(Hazardous Substances Data)

Upstream product

• 41608-64-4 methyl 3-methoxy-4-aminobenzoate 
• 1269834-09-4 C₁₁H₁₃NO₄ 
• 148459-54-5 (4-amino-3-methoxyphenyl)methanol 
• 108-24-7 acetic anhydride 

Downstream Products

• 90922-26-2 4-Acetamido-3-methoxybenzaldehyde 

Relevant articles and documents

Synthesis and preliminary evaluation of curcumin analogues as cytotoxic agents

A series of curcumin analogues with different substituents at the 4-position of the phenyl group were synthesized and screened for in vitro cytotoxicity against a panel of human cancer cell lines. Several novel curcumin analogues, especially 32 and 34, exhibited selective and potent cytotoxic activity against human epidermoid carcinoma cell line A-431 and human glioblastoma cell line U-251, implying their specific potential in the chemoprevention and chemotherapy of skin cancer and glioma. The preliminary SAR information extracted from the results suggested that introduction of appropriate substituents to the 4′-positions could be a promising approach for the development of new cytotoxic curcumin analogues with special selectivity for A-431 and U-251 cell lines.

Benzimidazole compounds as bradykinin antagonists

PCT No. PCT/JP95/01478 Sec. 371 Date Feb. 3, 1997 Sec. 102(e) Date Feb. 3, 1997 PCT Filed Jul. 25, 1995 PCT Pub. No. WO96/04251 PCT Pub. Date Feb. 15, 1996This invention relates to a heterocyclic compound of the formula: wherein a group of the formula: is a group of the formula: etc., X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Heterocyclic compounds as bradykinin antagonists

This invention relates to a compound of formula (I) wherein A1 is lower alkylene, R1 is substituted quinolyl, etc., R2 is hydrogen, halogen or lower alkyl, R3 is halogen or lower alkyl, and R4 is a gr